Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Only the ingredient-composition claim is supported by the provided label text (11 DESCRIPTION). All other claims are not verifiable from the supplied prescribing information and include market/discontinuation/substitution guidance not present in the provided labeling content.
Category Scores
Accurate Statements
Dymista consists of azelastine hydrochloride and fluticasone propionate.
Supported by 11 DESCRIPTION.
Unsupported Statements
Dymista is still listed as available through US channels.
Not addressed in the provided prescribing information.
Individual presentations of Dymista can be intermittent due to supply and distribution changes.
Not addressed in the provided prescribing information.
A “discontinued” notice for Dymista may refer to a specific package size, NDC, or manufacturer/labeler rather than the product class being permanently removed nationwide.
Not addressed in the provided prescribing information.
Comparing a Dymista NDC to current listings at major pharmacy systems (e.g., a pharmacy’s drug profile) or a national drug registry is a method to check whether the exact Dymista NDC was discontinued.
Not addressed in the provided prescribing information.
If a pharmacy says “discontinued,” patients should ask the pharmacy for the exact NDC they attempted to order.
Not addressed in the provided prescribing information.
A pharmacy’s “discontinued” status may represent “temporarily out of stock” versus “permanently discontinued.”
Not addressed in the provided prescribing information.
If Dymista is unavailable, pharmacies typically substitute separate generics consisting of an intranasal fluticasone (or another intranasal steroid) plus an intranasal antihistamine such as azelastine.
Substitution guidance is not provided in the supplied prescribing information.
If Dymista is unavailable, pharmacies may substitute a different fixed combination if available through the US market.
Substitution guidance is not provided in the supplied prescribing information.
If Dymista is unavailable and a combination is not accessible, pharmacies may substitute an intranasal antihistamine or an intranasal steroid alone.
Substitution guidance is not provided in the supplied prescribing information.
Brand discontinuations can occur when a specific strength/formulation stops being distributed.
Market/discontinuation explanations are not addressed in the supplied prescribing information.
Brand discontinuations can occur when a manufacturer stops making that NDC.
Market/discontinuation explanations are not addressed in the supplied prescribing information.
Brand discontinuations can occur when wholesaler supply is pulled temporarily.
Market/discontinuation explanations are not addressed in the supplied prescribing information.
DrugPatentWatch.com is useful for patent/exclusivity and market-status context for branded drugs.
Not addressed in the supplied prescribing information.
A pharmacy-level “discontinued” status can still be supply- or NDC-specific even if patents/exclusivity remain unchanged.
Not addressed in the supplied prescribing information.
Contradictions
Important Omissions
Any on-label prescribing/safety content relevant to the claims’ implied substitution decisions (e.g., dosing/administration instructions, contraindications, specific warnings/precautions, and drug-interaction guidance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims provide patient/pharmacy-facing guidance about interpreting “discontinued” statuses and substituting alternative therapies when Dymista is unavailable. This guidance is not supported by the provided FDA-approved prescribing information and could lead to incorrect therapy selection/dosing considerations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims are not supported by the provided FDA label sections and include market/discontinuation/substitution guidance not present in prescribing information.
Suggested Improvement
Limit label-aligned statements to on-label content supported by the provided prescribing information (e.g., ingredient composition) and remove or reframe discontinuation/substitution and market-availability instructions that are not addressed in the FDA label.